Connect Biopharma is trading 5.9% up at $2.33 in pre-market on light liquidity and a positive risk tone, rebounding modestly after recent volatility around the $2.20 level.
- No fresh company-specific headlines, earnings, FDA decisions, or major analyst actions have been reported since the last close.
- The move lacks a defined corporate catalyst and appears driven by broader market sentiment rather than a specific event.